Israel Active

Sheba Medical Center has deployed a new accelerated, AI-powered cancer diagnostics research platform to improve patient diagnosis, treatment, and outcomes. It utilizes solutions of various Israeli startups, including that of Imagene (see previously).

Healthcare app Together by Renee is integrating the video-based biomarker check technology from Israel’s Binah.ai (see previously). The platform allows US seniors to easily check and share vital signs with caregivers and family, using their smartphone cameras.

Joint Israeli & US research has revealed crucial insights into the early development of specialized tissues that protect the fetus during human pregnancy. The findings can potentially help prevent dangerous pregnancy complications, like pre-eclampsia and preterm birth.

Israel’s Sofwave Medical (see previously) has received US FDA approval for its treatment for acne scars. 88% of patients reported an improvement in a clinical study of Sofwave’s Synchronous Ultrasound Parallel Beam (SUPERB) technology.

Israel’s Neurosteer (see previously) has developed a musical test for the early detection of Parkinson’s Disease as well as Alzheimer’s and other forms of dementia.  Patients conduct a series of musical tasks while sensors connected to an EEG device record their brain activity.

Israel’s BioProtect (see previously) has received US FDA's clearance for its biodegradable balloon spacer that protects healthy tissue against damage during prostate cancer radiation therapy.  BioProtect already has approval for the European market.

Researchers at Israel’s Ariel University have enhanced the ability of Photodynamic cancer therapy (PDT) to reach tumors deep inside the body. They used nanoparticles of barium titanate, curcumin (turmeric) and pulsed lasers to optimize the Near Infrared Light.

Israel’s MediWound (see previously) announced positive data from its Phase I/II study of MW005 for non-surgical treatment of Basal Cell Carcinoma (BCC) – a form of slow-growing skin cancer.  MW005 is safe, well-tolerated and completely cleared the BCC lesions.

Researchers at Tel Aviv University (TAU) have developed a computational model that makes it possible to predict an individual woman’s genetic risk of developing breast cancer based on her genetic profile. It means women at risk can be tested earlier and more frequently.

Israel’s Nevia Bio (previously Gina Life) specializes in women’s health, using its innovative machine-learning platform to detect diseases while they are still curable. Nevia is initially targeting ovarian cancer, which has a less than 20% survival rate at stage 3 and currently has no early detection.